Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous nivolumab pharmacokinetic multi-tumor study
NL-OMON55364Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and ENHANZE in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), melanoma and 2 more (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Pharmacokinetics of subcutaneous nivolumab. Started Jul 2019; status: recruiting.
02
Drugs
nivolumabENHANZE
03
Conditions
non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)melanomahepatocellular carcinoma (HCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON55364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55364.